Danish pharmaceutical company Lundbeck had hoped for quick, efficient results in the third clinical trial with Rexulti as a treatment for agitation in Alzheimer's patients, but this hope was soon extinguished.
That's the lay of the land early on Tuesday, after Lundbeck and partner company Otsuka stated that they would carry on the phase III trial with the drug after having received a new independent analysis of the preliminary results. Lundbeck plans to enroll all 330 patients, which the trial was scheduled for, and it will not discontinue the trial now, after having studied only 255 patients.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.